Nicola D. Thompson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nicola D. Thompson has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Shelley S. Magill
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
4 shared publicationsDeborah Thompson
New Mexico Emerging Infections Program, New Mexico Department of Health, Santa Fe, NM
3 shared publicationsGhinwa Dumyati
University of Rochester, Rochester, NY; Emerging Infections Program, Rochester, NY
3 shared publicationsJonathan R. Edwards
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
3 shared publicationsJoseph F. Perz
From the*Epidemic Intelligence Service, †Division of Viral Hepatitis, Epidemiology and Surveillance Branch, and ∥Division of Healthcare Quality Promotion, Prevention and Response Branch, Centers for Disease Control and Prevention, Atlanta, Georgia; ‡Florida Epidemic Intelligence Service, Florida Department of Health, Tallahassee, Florida; and §Epidemiology Program, Pinellas County Health Department, St. Petersburg, Florida
3 shared publicationsMeghan Maloney
Connecticut Emerging Infections Program, Connecticut Department of Public Health, Hartford, CT
3 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (11)
Estimating New Viral Hepatitis Infections From Reported Acute Cases in the United States
Background: New viral hepatitis infections may go unreported because many infections are asymptomatic, some people with symptoms do not seek testing, and gaps in surveillance capacity limit identification of acute cases. We present an updated approach to estimate the burden of new viral hepatitis infections from reported acute cases. Methods: We estimated the proportion of new viral hepatitis infections expected to be symptomatic from the literature and the proportion of symptomatic patients expected to seek testing from a national survey. We estimated reporting proportions for new hepatitis A virus (HAV) and hepatitis B virus (HBV) infections from the literature and developed a Poisson regression model to estimate the proportion of new hepatitis C virus (HCV) infections reported as acute cases based on predictors of jurisdictional surveillance capacity. Results: Overall multipliers to adjust reported acute cases in 2022 ranged from 1.6 (95% uncertainty interval [95% UI] 1.4–2.1) to 2.6 (2.0–3.6) across jurisdictions for hepatitis A, 5.7 (3.1–21.7) to 9.1 (4.7–35.1) for acute hepatitis B, and 2.8 (2.1–3.9) to 67.3 (33.8–140.8) for acute hepatitis C. Applying these multipliers, estimated numbers of new HAV, HBV, and HCV infections in 2022 nationally were 4732 (95% UI 4344–5387), 15 725 (13 515–35 455), and 39 734 (31 212–57 515), respectively. Conclusions: Reported cases might substantially underestimate new viral hepatitis infections, and adjustment factors vary widely by jurisdiction. Our updated approach enables public health officials to estimate the burden of new viral hepatitis infections more accurately for program planning and evaluation.
- 15 October 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (11)
Open AccessEstimating New Viral Hepatitis Infections From Reported Acute Cases in the United States
Background: New viral hepatitis infections may go unreported because many infections are asymptomatic, some people with symptoms do not seek testing, and gaps in surveillance capacity limit identification of acute cases. We present an updated approach to estimate the burden of new viral hepatitis infections from reported acute cases. Methods: We estimated the proportion of new viral hepatitis infections expected to be symptomatic from the literature and the proportion of symptomatic patients expected to seek testing from a national survey. We estimated reporting proportions for new hepatitis A virus (HAV) and hepatitis B virus (HBV) infections from the literature and developed a Poisson regression model to estimate the proportion of new hepatitis C virus (HCV) infections reported as acute cases based on predictors of jurisdictional surveillance capacity. Results: Overall multipliers to adjust reported acute cases in 2022 ranged from 1.6 (95% uncertainty interval [95% UI] 1.4–2.1) to 2.6 (2.0–3.6) across jurisdictions for hepatitis A, 5.7 (3.1–21.7) to 9.1 (4.7–35.1) for acute hepatitis B, and 2.8 (2.1–3.9) to 67.3 (33.8–140.8) for acute hepatitis C. Applying these multipliers, estimated numbers of new HAV, HBV, and HCV infections in 2022 nationally were 4732 (95% UI 4344–5387), 15 725 (13 515–35 455), and 39 734 (31 212–57 515), respectively. Conclusions: Reported cases might substantially underestimate new viral hepatitis infections, and adjustment factors vary widely by jurisdiction. Our updated approach enables public health officials to estimate the burden of new viral hepatitis infections more accurately for program planning and evaluation.
- 31 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (8)
Antimicrobial Use in U.S. Hospitals: Comparison of 2015 and 2023 Prevalence Surveys
Background: Prevalence surveys in U.S. hospitals in 2011 and 2015 showed that half of inpatients received antimicrobials on the survey day or day before. We repeated the survey in 2023 to assess changes in antimicrobial use (AU). Methods: Ten Emerging Infections Program (EIP) sites recruited up to 25 hospitals each, prioritizing prior participants. EIP staff reviewed medical records of randomly selected inpatients from the survey day morning census and documented AU on the survey day or day before. We compared AU and stewardship characteristics between 2023 and 2015 and used multivariable log-binomial regression to identify factors associated with AU in 2023. Results: Antimicrobial stewardship programs were present in 215/218 hospitals in 2023 (98.6%) compared with 158/199 (79.4%) in 2015. Of 13 653 patients in 2023, 6785 (49.7%) received ≥1 antimicrobial on the survey day or day before. Among 151 hospitals participating in both surveys, overall AU prevalence was similar in 2015 and 2023 (49.2% vs 49.1%), with decreases in neonatal critical care (23.4% to 17.1%) and increases in mother–baby units (24.4% to 32.8%). Fluoroquinolone use declined (9.2% to 2.8%), while third- or fourth-generation cephalosporin use increased (12.3% to 18.6%). In 2023, higher AU was associated with patient factors (medical devices, inpatient location, obesity, 4–17 day hospital stays, and suburban residence) and hospital factors (Northeast and South regions, AU audits). Conclusions: One in two inpatients received an antimicrobial in 2023, similar to 2015. However, changes in AU by inpatient location and antimicrobial class suggest evolving prescribing practices and may inform targeted surveillance and stewardship efforts.
- 31 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (8)
Antimicrobial Use in U.S. Hospitals: Comparison of 2015 and 2023 Prevalence Surveys
Background: Prevalence surveys in U.S. hospitals in 2011 and 2015 showed that half of inpatients received antimicrobials on the survey day or day before. We repeated the survey in 2023 to assess changes in antimicrobial use (AU). Methods: Ten Emerging Infections Program (EIP) sites recruited up to 25 hospitals each, prioritizing prior participants. EIP staff reviewed medical records of randomly selected inpatients from the survey day morning census and documented AU on the survey day or day before. We compared AU and stewardship characteristics between 2023 and 2015 and used multivariable log-binomial regression to identify factors associated with AU in 2023. Results: Antimicrobial stewardship programs were present in 215/218 hospitals in 2023 (98.6%) compared with 158/199 (79.4%) in 2015. Of 13 653 patients in 2023, 6785 (49.7%) received ≥1 antimicrobial on the survey day or day before. Among 151 hospitals participating in both surveys, overall AU prevalence was similar in 2015 and 2023 (49.2% vs 49.1%), with decreases in neonatal critical care (23.4% to 17.1%) and increases in mother–baby units (24.4% to 32.8%). Fluoroquinolone use declined (9.2% to 2.8%), while third- or fourth-generation cephalosporin use increased (12.3% to 18.6%). In 2023, higher AU was associated with patient factors (medical devices, inpatient location, obesity, 4–17 day hospital stays, and suburban residence) and hospital factors (Northeast and South regions, AU audits). Conclusions: One in two inpatients received an antimicrobial in 2023, similar to 2015. However, changes in AU by inpatient location and antimicrobial class suggest evolving prescribing practices and may inform targeted surveillance and stewardship efforts.
- 22 July 2024
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 30 (5) , 733-743
Estimating the Prevalence of Injection Drug Use Among Acute Hepatitis C Cases From a National Surveillance System: Application of Random Forest-Based Multiple Imputation
Background: Injection drug use (IDU) is a major contributor to the syndemic of viral hepatitis, human immunodeficiency virus, and drug overdose. However, information on IDU is frequently missing in national viral hepatitis surveillance data, which limits our understanding of the full extent of IDU-associated infections. Multiple imputation by chained equations (MICE) has become a popular approach to address missing data, but its application for IDU imputation is less studied. Methods: Using the 2019-2021 National Notifiable Diseases Surveillance System acute hepatitis C case data and publicly available county-level measures, we evaluated listwise deletion (LD) and 3 models imputing missing IDU data through MICE: parametric logistic regression, semi-parametric predictive mean matching (PMM), and nonparametric random forest (RF) (both standard RF [sRF] and fast implementation of RF [fRF]). Results: The estimated IDU prevalence among acute hepatitis C cases increased from 63.5% by LD to 65.1% by logistic regression, 66.9% by PMM, 76.0% by sRF, and 85.1% by fRF. Evaluation studies showed that RF-based MICE imputation, especially fRF, has the highest accuracy (as measured by smallest raw bias, percent bias, and root mean square error) and highest efficiency (as measured by smallest 95% confidence interval width) compared to LD and other models. Sensitivity analyses indicated that fRF remained robust when data were missing not at random. Conclusion: Our analysis suggested that RF-based MICE imputation, especially fRF, could be a valuable approach for addressing missing IDU data in the context of population-based surveillance systems like National Notifiable Diseases Surveillance System. The inclusion of imputed IDU data may enhance the effectiveness of future surveillance and prevention efforts for the IDU-driven syndemic.
- 22 July 2024
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 30 (5) , 733-743
Estimating the Prevalence of Injection Drug Use Among Acute Hepatitis C Cases From a National Surveillance System: Application of Random Forest-Based Multiple Imputation
Background: Injection drug use (IDU) is a major contributor to the syndemic of viral hepatitis, human immunodeficiency virus, and drug overdose. However, information on IDU is frequently missing in national viral hepatitis surveillance data, which limits our understanding of the full extent of IDU-associated infections. Multiple imputation by chained equations (MICE) has become a popular approach to address missing data, but its application for IDU imputation is less studied. Methods: Using the 2019-2021 National Notifiable Diseases Surveillance System acute hepatitis C case data and publicly available county-level measures, we evaluated listwise deletion (LD) and 3 models imputing missing IDU data through MICE: parametric logistic regression, semi-parametric predictive mean matching (PMM), and nonparametric random forest (RF) (both standard RF [sRF] and fast implementation of RF [fRF]). Results: The estimated IDU prevalence among acute hepatitis C cases increased from 63.5% by LD to 65.1% by logistic regression, 66.9% by PMM, 76.0% by sRF, and 85.1% by fRF. Evaluation studies showed that RF-based MICE imputation, especially fRF, has the highest accuracy (as measured by smallest raw bias, percent bias, and root mean square error) and highest efficiency (as measured by smallest 95% confidence interval width) compared to LD and other models. Sensitivity analyses indicated that fRF remained robust when data were missing not at random. Conclusion: Our analysis suggested that RF-based MICE imputation, especially fRF, could be a valuable approach for addressing missing IDU data in the context of population-based surveillance systems like National Notifiable Diseases Surveillance System. The inclusion of imputed IDU data may enhance the effectiveness of future surveillance and prevention efforts for the IDU-driven syndemic.
- Open Access
- 1 June 2018
- Published by Elsevier in American Journal of Infection Control
- Vol. 46 (6) , 637-642
The National Healthcare Safety Network Long-term Care Facility Component early reporting experience: January 2013-December 2015
- 1 June 2018
- Published by Elsevier in American Journal of Infection Control
- Vol. 46 (6) , 637-642
Open AccessThe National Healthcare Safety Network Long-term Care Facility Component early reporting experience: January 2013-December 2015
- 1 December 2016
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 17 (12) , 1151-1153
Prevalence of Antimicrobial Use and Opportunities to Improve Prescribing Practices in U.S. Nursing Homes
- 1 December 2016
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 17 (12) , 1151-1153
Prevalence of Antimicrobial Use and Opportunities to Improve Prescribing Practices in U.S. Nursing Homes
- 14 January 2016
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 37 (4) , 472-474
Evaluation of Manual and Automated Bloodstream Infection Surveillance in Outpatient Dialysis Centers
Outpatient hemodialysis bloodstream infection rates, now used for performance measurement and were significantly higher for manual compared with automated surveillance (P<.001), largely owing to the absence of blood culture data in the dialysis electronic health record. Improvement in data sharing between hospitals and outpatient dialysis centers is necessary. Infect. Control Hosp. Epidemiol. 2016;37(4):472–474
- 14 January 2016
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 37 (4) , 472-474
Evaluation of Manual and Automated Bloodstream Infection Surveillance in Outpatient Dialysis Centers
Outpatient hemodialysis bloodstream infection rates, now used for performance measurement and were significantly higher for manual compared with automated surveillance (P<.001), largely owing to the absence of blood culture data in the dialysis electronic health record. Improvement in data sharing between hospitals and outpatient dialysis centers is necessary. Infect. Control Hosp. Epidemiol. 2016;37(4):472–474
- 21 October 2015
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 37 (1) , 19-25
Evaluating the Use of the Case Mix Index for Risk Adjustment of Healthcare-Associated Infection Data: An Illustration using Clostridium difficile Infection Data from the National Healthcare Safety Network
BACKGROUND: Case mix index (CMI) has been used as a facility-level indicator of patient disease severity. We sought to evaluate the potential for CMI to be used for risk adjustment of National Healthcare Safety Network (NHSN) healthcare-associated infection (HAI) data.METHODS: NHSN facility-wide laboratory-identified Clostridium difficile infection event data from 2012 were merged with the fiscal year 2012 Inpatient Prospective Payment System (IPPS) Impact file by CMS certification number (CCN) to obtain a CMI value for hospitals reporting to NHSN. Negative binomial regression was used to evaluate whether CMI was significantly associated with healthcare facility-onset (HO) CDI in univariate and multivariate analysis.RESULTS: Among 1,468 acute care hospitals reporting CDI data to NHSN in 2012, 1,429 matched by CCN to a CMI value in the Impact file. CMI (median, 1.49; interquartile range, 1.36–1.66) was a significant predictor of HO CDI in univariate analysis (P<.0001). After controlling for community onset CDI prevalence rate, medical school affiliation, hospital size, and CDI test type use, CMI remained highly significant (P<.0001), with an increase of 0.1 point in CMI associated with a 3.4% increase in the HO CDI incidence rate.CONCLUSIONS: CMI was a significant predictor of NHSN HO CDI incidence. Additional work to explore the feasibility of using CMI for risk adjustment of NHSN data is necessary.Infect. Control Hosp. Epidemiol. 2015;37(1):19–25
- 21 October 2015
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 37 (1) , 19-25
Evaluating the Use of the Case Mix Index for Risk Adjustment of Healthcare-Associated Infection Data: An Illustration using Clostridium difficile Infection Data from the National Healthcare Safety Network
BACKGROUND: Case mix index (CMI) has been used as a facility-level indicator of patient disease severity. We sought to evaluate the potential for CMI to be used for risk adjustment of National Healthcare Safety Network (NHSN) healthcare-associated infection (HAI) data.METHODS: NHSN facility-wide laboratory-identified Clostridium difficile infection event data from 2012 were merged with the fiscal year 2012 Inpatient Prospective Payment System (IPPS) Impact file by CMS certification number (CCN) to obtain a CMI value for hospitals reporting to NHSN. Negative binomial regression was used to evaluate whether CMI was significantly associated with healthcare facility-onset (HO) CDI in univariate and multivariate analysis.RESULTS: Among 1,468 acute care hospitals reporting CDI data to NHSN in 2012, 1,429 matched by CCN to a CMI value in the Impact file. CMI (median, 1.49; interquartile range, 1.36–1.66) was a significant predictor of HO CDI in univariate analysis (P<.0001). After controlling for community onset CDI prevalence rate, medical school affiliation, hospital size, and CDI test type use, CMI remained highly significant (P<.0001), with an increase of 0.1 point in CMI associated with a 3.4% increase in the HO CDI incidence rate.CONCLUSIONS: CMI was a significant predictor of NHSN HO CDI incidence. Additional work to explore the feasibility of using CMI for risk adjustment of NHSN data is necessary.Infect. Control Hosp. Epidemiol. 2015;37(1):19–25
- 1 August 2015
- Published by Elsevier in American Journal of Infection Control
- Vol. 43 (8) , 853-856
Estimating central line–associated bloodstream infection incidence rates by sampling of denominator data: A prospective, multicenter evaluation
- 1 August 2015
- Published by Elsevier in American Journal of Infection Control
- Vol. 43 (8) , 853-856
Estimating central line–associated bloodstream infection incidence rates by sampling of denominator data: A prospective, multicenter evaluation
- 1 March 2013
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 34 (3) , 221-228
Evaluating the Accuracy of Sampling to Estimate Central Line–Days Simplification of the National Healthcare Safety Network Surveillance Methods
Evaluating the Accuracy of Sampling to Estimate Central Line–Days Simplification of the National Healthcare Safety Network Surveillance Methods - Volume 34 Issue 3 - Nicola D. Thompson, Jonathan R. Edwards, Wendy Bamberg, Zintars G. Beldavs, Ghinwa Dumyati, Deborah Godine, Meghan Maloney, Marion Kainer, Susan Ray, Deborah Thompson, Lucy Wilson, Shelley S. Magill
- 1 March 2013
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 34 (3) , 221-228
Evaluating the Accuracy of Sampling to Estimate Central Line–Days Simplification of the National Healthcare Safety Network Surveillance Methods
Evaluating the Accuracy of Sampling to Estimate Central Line–Days Simplification of the National Healthcare Safety Network Surveillance Methods - Volume 34 Issue 3 - Nicola D. Thompson, Jonathan R. Edwards, Wendy Bamberg, Zintars G. Beldavs, Ghinwa Dumyati, Deborah Godine, Meghan Maloney, Marion Kainer, Susan Ray, Deborah Thompson, Lucy Wilson, Shelley S. Magill
- 7 June 2012
- Published by Wolters Kluwer Health in American Journal of Medical Quality
- Vol. 28 (1) , 56-59
Investigating Systematic Misclassification of Central Line–Associated Bloodstream Infection (CLABSI) to Secondary Bloodstream Infection During Health Care–Associated Infection Reporting
Central line-associated bloodstream infection (CLABSI) rates are an important measure of health care quality. However, reputational or financial risks associated with public reporting and disclosure of hospital CLABSI rates may introduce reporting biases, including intentional underreporting. To assess systematic case misclassification of CLABSI to secondary bloodstream infection (BSI; ie, intentional underreporting of CLABSI), the authors assessed data reported to the National Healthcare Safety Network by hospitals in Pennsylvania, the only state in which both CLABSI and secondary BSI reporting are mandatory. CLABSI rates decreased over the 2-year analysis period, but the authors found no evidence of increasing secondary BSI rates, suggesting that systematic case misclassification is not widespread.
- 7 June 2012
- Published by Wolters Kluwer Health in American Journal of Medical Quality
- Vol. 28 (1) , 56-59
Investigating Systematic Misclassification of Central Line–Associated Bloodstream Infection (CLABSI) to Secondary Bloodstream Infection During Health Care–Associated Infection Reporting
Central line-associated bloodstream infection (CLABSI) rates are an important measure of health care quality. However, reputational or financial risks associated with public reporting and disclosure of hospital CLABSI rates may introduce reporting biases, including intentional underreporting. To assess systematic case misclassification of CLABSI to secondary bloodstream infection (BSI; ie, intentional underreporting of CLABSI), the authors assessed data reported to the National Healthcare Safety Network by hospitals in Pennsylvania, the only state in which both CLABSI and secondary BSI reporting are mandatory. CLABSI rates decreased over the 2-year analysis period, but the authors found no evidence of increasing secondary BSI rates, suggesting that systematic case misclassification is not widespread.